Viking Therapeutics unveiled Phase 2 results for its once-daily obesity pill, VK2735, showing up to 12.2 percent average weight loss after 13 weeks. Yet investors punished the stock, a reaction one analyst dismissed as “extreme,” underscoring the fierce competition from Eli Lilly’s tirzepatide.